Recon: Novartis to buy RNA developer Avidity in $12B deal; Intellia halts gene therapy trials following patient liver injury

• Generic drugmakers seek to thwart a Connecticut law that would cap rising prices (STAT)
• Novartis to buy RNA-focused Avidity in $12 billion deal (STAT)
• J&J Talc Cancer Suits Rise 17% After Failed Settlement Effort (Bloomberg)
• CMS calls back furloughed employees to help with Medicare, ACA enrollment periods (MedTech Dive)
• Merck nabs updated FDA label for PAH med Winrevair (Fierce Pharma)

• Chinese biotech industry shows no signs of slowing as threat of U.S. restrictions loom (STAT)
• Exclusive: Scottish microRNA startup claims signs of success in Phase 2 tendinopathy study (Endpoints)
• India advances anti-dumping probe into tuberculosis drug imports from China, Thailand (Reuters)
• Reworked German Hospital Reform Law Expected Q1 2026 After Critics Get Heard (MedTech Insight)
• Danaher Says China VBP Impact Now ‘Modest and Manageable’ As Diagnostic Headwinds Ease (MedTech Insight)
• UK Medtechs On A Journey To MARRS Find Welcome Regulatory Funding Support (MedTech Insight)
• UK watchdog slams AstraZeneca, Organon for marketing breaches (Fierce Pharma)

• All of a sudden, dementia treatment is becoming very exciting (STAT)
• Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern (STAT)
• CAR-T therapies from Cabaletta, Bristol Myers Squibb induce remissions in patients with autoimmune disorders (STAT)
• BridgeBio study data on drug for rare form of muscular dystrophy could set up approval (STAT)
• Zenas’ multiple sclerosis drug slows new brain lesions in mid-stage trial (Endpoints)
• FDA approves Syndax’s menin inhibitor with black-box warning; GSK’s ADC deal (Endpoints)
• BridgeBio shifts filing plans for rare disease drug after Phase 3 success (Endpoints)
• Neumora moves forward with NLRP3 in obesity after Ventyx's drug failed to deliver weight loss (Endpoints)
• Hemab nabs $157M to finance the 'ultimate coagulation disorder' biotech (Endpoints)
• Novo-backed MapLight valued at $787 million after shares jump in Nasdaq debut (Reuters)
• Organon CEO Kevin Ali to resign after probe into contraceptive sales (Reuters)

• WuXi AppTec to divest clinical services to focus on manufacturing business (Endpoints)
• Revvity lifts profit forecast on renewed demand in diagnostics unit (Reuters)
• Corcym, CardioPrecision set sights on robotic heart valve replacement (MedTech Dive)
• J&J awards first grants from AI surgery fund (MedTech Dive)
• Medtech industry closely watching Section 232 investigation (MedTech Dive)
• Accuray hires Steve La Neve as CEO in transformation effort (MedTech Dive)

• Food giants may lean more on lawsuits as private label encroaches on their turf (Food Dive)
• Food industry prepares to fight MAHA in states (Food Dive)

• ‘From Diagnostics To Prognostics’: Google Cloud Healthcare Director Sees AI As Healthcare’s Future (MedTech Insight)
• Could Oura Take A Bite Out Of Apple? Company Seeks FDA Clearance For Blood Pressure Feature (MedTech Insight)
• Trump offers new warning on Tylenol for pregnant women (The Hill)
• Why new mpox cases in California are raising concerns (The Hill)